Drug Approval | December 27, 2022
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The company is making its entry into the Hyderabad market through its unique asset-light business model
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated
